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A case of Bartter syndrome type I with atypical 
presentations
Bartter syndrome (BS) is an autosomal recessively inherited rare renal 
tubular disorder characterized by hypokalemic metabolic alkalosis 
and hyperreninemic hyperaldosteronism with normal to low blood 
pressure due to a renal loss of sodium. Genetically, BS is classified 
into 5 subtypes according to the underlying genetic defects, and BS 
is clinically categorized into antenatal BS and classical BS according 
to onset age. BS type I is caused by loss-of-function mutations in 
the SLC12A1 gene and usually manifests as antenatal BS. This report 
concerns a male patient with compound heterozygous missense 
mutations on SLC12A1 (p.C436Y and p.L560P) and atypical clinical 
and laboratory features. The patient had low urinary sodium and 
chloride levels without definite metabolic alkalosis until the age of 
32 months, which led to confusion between BS and nephrogenic 
diabetes insipidus (NDI). In addition, the clinical onset of the patient 
was far beyond the neonatal period. Genetic study eventually led 
to the diagnosis of BS type I. The low urinary sodium and chloride 
concentrations may be caused by secondary NDI, and the later onset 
may suggest the existence of a genotype-phenotype correlation. In 
summary, BS type I may have phenotype variability including low 
urine sodium and chloride levels and later onset. A definitive diagnosis 
can be confirmed by genetic testing.
Key words: Bartter syndrome, Nephrogenic diabetes insipidus, 
SLC12A1 gene, Child
Eun Hye Lee, M.D.
1, Ju Sun Heo, M.D.
1, Hyun 
Kyung Lee, M.D.
1, Kyung Hee Han, M.D.
1, Hee 
Gyung Kang, M.D.
1,2, II Soo Ha, M.D.
1,3, Yong 
Choi, M.D.
1, and Hae Il Cheong, M.D.
1,2,3
Department of Pediatrics
1, Seoul National University 
Children’s Hospital, Seoul, Korea 
Research Center for Rare Diseases
2, Seoul National 
University Hospital, Seoul, Korea
Kidney Research Institute
3, Medical Research Center, 
Seoul National University College of Medicine, Seoul, 
Korea
Received: 21 May 2010, Revised: 23 June 2010
Accepted: 14 July 2010
Corresponding author: Hae Il Cheong, M.D.
Department of Pediatrics, Seoul National University 
Children’s Hospital, 101 Daehang-ro, Jongno-gu, Seoul 110-
744, Korea
Tel: +82.2-2072-2810, Fax:+82.2-743-3455  
E-mail: cheonghi@snu.ac.kr 
Copyright © 2010 by The Korean Pediatric Society
Introduction
The hallmarks of Bartter syndrome (BS) are renal salt wasting 
and hypokalemic metabolic alkalosis accompanied by normal 
or low blood pressure despite secondary hyperaldosteronism
1). 
BS is clinically categorized into antenatal BS and classical BS
2). 
Antenatal BS is severe, early-onset form, characterized by maternal 
polyhydramnios, prematurity, intrauterine and postnatal polyuria, 
hypercalciuria, nephrocalcinosis, normomagnesemia, recurrent 
vomiting, growth retardation, increased renal synthesis and urinary 
excretion of prostaglandin
3-5). Classical BS is associated with 
milder phenotype with a later onset beginning from infancy to 
adolescence. BS is caused by genetic disruptions of ion transporters 
or channels in the thick ascending limb of loop of Henle
6); BS type 
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.810      EH Lee, et al. • A case of Bartter syndrome type I with atypical presentations
I is caused by loss-of-function mutations of SLC12A1 encoding 
the apical sodium-potassium-chloride cotransporter (NKCC2), 
BS type II by loss-of-function mutations of KCNJ1 encoding 
the apical inwardly-rectifying potassium channel (ROMK), BS 
type III by loss-of-function mutations of CLCNKB encoding 
the basolateral chloride channel (ClC-Kb), BS type IV by loss-of-
function mutations of BSND encoding barttin, and BS type V 
by gain-of-function mutations of CASR encoding the basolateral 
calcium sensing receptor (CaSR)
2). Patients with BS type I or II 
usually present as antenatal BS, and BS type III usually manifest as 
classic BS. BS type IV is specifically accompanied by sensorineural 
deafness, and BS type V is characterized by hypocalcemia due 
to hypoparathyroidism
2, 7-9). The cardinal manifestation of BS is 
metabolic alkalosis with increased urinary electrolytes due to renal 
salt wasting in the thick ascending limb of loop of Henle. Typical 
laboratory tests typically reveal urine potassium ≥20 mEq/L, urine 
chloride ≥20 mEq/L, serum bicarbonate ≥30 mEq/L, blood pH ≥ 
7.45, and increased serum renin and aldosterone levels. 
Here, we report a case with BS type I with later onset of atypical 
manifestations mimicking nephrogenic diabetes insipidus (NDI) 
such as low urine sodium and chloride concentrations without 
definite metabolic alkalosis. 
Case report
The patient was a 21-month-old male from healthy unrelated 
parents. He was prematurely born by elective caesarean section 
with a birth weight of 1,780 g at 33
+4 weeks of gestation (10-50th 
percentile for gestational age). The pregnancy was complicated 
by severe polyhydramnios, requiring several amniocenteses. 
Immediately after birth, he was admitted to the neonatal intensive 
care unit of a regional medical center for 21 days. A postnatal 
chromosome study revealed a karyotype of 47, XYY. At the age of 1 
month, he developed frequent vomiting. At the age of 7 months, his 
mother tried a weaning diet but failed because he could not swallow 
any solid foods. However, his growth was normal. 
At the age of 13 months, he developed urinary tract infection. At 
that time, his height was 78.6 cm (50-75th percentile), weight 10.5 
kg (50-75th percentile), and head circumference 46.5 cm (50-75th 
percentile). However, his development was retarded as 8-month-old 
state. In addition, suspicious bilateral medullary nephrocalcinosis 
were detected by renal ultrasonography. 
At the age of 17 months, he was evaluated at a local hospital due to 
continuous vomiting. His height was 83.5 cm (75-90th percentile), 
weight 11.5 kg (50-75th percentile) and head circumference 47.5 
cm (50-75th percentile). Development was a 9-month-old state. 
Brain MRI revealed slightly increased subarachnoid space, and 
esophagography was normal. At that time, hypokalemia was 
detected for the first time and kidney ultrasonography revealed 
definite bilateral medullary nephrocalcinosis. Thereafter, he could 
not grow adequately but began to lose his weight. He was referred 
to our hospital at the age of 21 months for further evaluation. 
A thorough evaluation of the patient was done at our hospital. He 
did not have frequent vomiting any more, but he still had difficulty 
Fig. 1. Growth curve of our patient.
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eating a solid diet. When solids were put in his mouth, he sucked 
out the fluids and then spat out the remainder of the food. His diet 
consisted of 2-2.5 L of liquid materials and urine output was 1.5-
2 liters a day. His body weight was 10.8 kg (third-fifth percentile), 
height 89.9 cm (50-75th percentile) and head circumference 48 
cm (10-25th percentile). He could walk but with unstable walking 
posture. He could not climb up the stairs. He could speech simple 
words such as mamma, papa, water and sister, but he could not 
speak a sentence. His blood pressure was 100/54 mmHg. Dental 
examination displayed generalized delayed tooth eruption state, but 
there were no decayed teeth or periodontal disease. Esophagography 
revealed slight degree of passage delay and minimal gastro-
esophageal reflux. Brain computed tomography showed no 
abnormality. Plasma renin activity was 40.8 ng/mL/hr (normal 
range <16 ng/mL/hr), and serum aldosterone 888 pg/mL (normal 
50-194). Serum sodium level was 140 mmol/L, potassium 3 mmol/
L, and total CO2 25-31 mmol/L. Serum calcium level was 10.5 mg/
dL, phosphorus 5.2 mg/dL, magnesium 2.4 mEq/L, creatinine 
0.5 mg/dL. Urine specific gravity was 1.003, and there was no 
proteinuria or hematuria. In spot urine, sodium concentration 
was 7 mmol/L, potassium 38.5 mmol/L, chloride 9 mmol/L, and 
calcium (5.0 mg/dL) to creatinine (3.3 mg/dL) ratio 1.52. Tubular 
reabsorption of phosphate was 82%, and trans-tubular potassium 
gradient was 13.78 (normal <2). 
After the evaluation, BS was suspected by clinical features 
including hypokalemia, hyperreninemia, hyperaldosteronemia, 
polyuria, hypercalciuria, and nephrocalcinosis. However, low 
urine electrolytes levels were inconsistent with BS. Thus, for 
the possibility of nephrogenic diabetes insipidus (NDI), water 
deprivation test and genetic test were done. After 12-hour water 
deprivation, urine specific gravity was 1.008 and urine osmolality 
276 mOsm/kg. We analyzed the causative genes of both BS and 
NDI, namely SLC12A1 encoding NKCC2, KCNJ1 encoding 
ROMK, CLCNKB encoding ClCKb, AVPR2 encoding arginine 
vasopressin V2 receptor and AQP2 encoding vasopressin- regulated 
water channel aquaporin 2 (AQP2). Compound heterozygous 
mutations in the SLC12A1 gene were detected; c.G1277A 
causing p.Cys(TGT)436Tyr(TAT) in exon 10 and c.T1679C 
causing p.Leu(CTT)560Pro(CCT) in exon 12. The former is a 
previously reported mutation in a patient with antenatal BS
10), and 
the latter is a novel mutation. L560P mutation was not detected 
in 50 control Korean and 50 control Japanese. In addition, two 
computer programs (the Scale-Invariant Feature Transform (SIFT, 
http://blocks.fhcrc.org/sift/SIFT.html) and the Polymorphism 
Phenotyping (Polyphen, http://genetics.bwh.harvard.edu/pph/) 
predicted that L560P substitution would be pathogenic. There was 
no pathogenic mutation in other genes tested.
After confirming the genetic diagnosis of BS type I, indo-
methacin therapy was started with a dosage of 0.05 mg/kg/day, and 
the dosage was increased to 0.2 mg/kg/day. This regimen was well 
tolerated and considerably improved his clinical course. At the last 
follow-up at the age of 29 months, his body weight was 13.2 kg (50-
75th percentile) and height was 91 cm (50-75th percentile).
Discussion
The diagnosis of BS type I in this patient was confirmed by 
genetic study. However, the patient had at least two atypical clinical 
features that are inconsistent with BS type I. In this patient, BS was 
clinically suspected first on the basis of typical laboratory findings 
including hypokalemia, hyperreninemia, hyperaldosteronemia, 
hypercalciuria, nephrocalcinosis as well as typical clinical features 
including normal or low blood pressure, polydipsia, polyuria, 
vomiting, maternal polyhydramnios and prematurity history. 
However, the urine sodium and chloride concentrations were 
persistently low and metabolic alkalosis was not definite (Table 1). 
Proesmans
5) reviewed the change in the urine electrolytes levels 
in patients with BS during neonatal and early infant periods and 
found that urine sodium (93-126 mmol/L) and chloride (89-
132 mmol/L) levels were high and potassium level was low (1-15 
mmol/L) during the neonatal period. However, after 3-6 weeks, 
urine sodium concentration decreased and the initially very low 
urine potassium levels started to increase. This transformation of 
renal sodium loss to renal potassium loss may be explained by a 
combined maturation of both the proximal and distal tubules, 
which results in compensation of urinary sodium loss but at the 
price of marked hyperaldosteronism. However, in our patient, data 
about urine electrolytes during the neonatal period were unavailable 
Table 1. Serial Laboratory Data of the Patient
Age 
(months)
Serum Spot urine
Na K Cl tCO2 Cr Na K Cl Cr
13
20
21
22
23
26
27
28
29
32
35
144
139
136
137
142
137
139
141
142
142
142
3.3
3.5
3.4
3.7
3.0
3.1
3.7
3.5
3.6
4.3
3.6
101
97
98
97
102
101
101
98
102
100
102
29
25
25
31
28
27
27
22
28
28
0.4
0.5
0.4
0.4
0.4
0.4
0.5
0.6
0.5
0.6
0.5
10
13
14
19
10
  8
23
21
24
19
18.2
29.3
19.1
19.9
18.7
34.4
20
24.1
30.1
34.5
12
13
  9
11
  8
17
23
25
16
  7.6
14.6
  7.5
12.6
  8.9
  8.8
16.8
Abbreviations: Cr, creatinine; tCO2, total CO2
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and the urinary chloride level was persistently low. Thus, possibility 
of combined primary or secondary NDI was considered in our 
patient. He showed almost no response to water deprivation test 
and genetic study of AVPR2 and AQP2 revealed no pathogenic 
mutation, which suggest that he had secondary NDI. Acquired 
NDI can develop secondary to various causes including relief of 
obstruction in obstructive uropathy, hypokalemia, renal failure, 
lithium toxicity and hypercalcemia
11). The expression of AQP2 
decreases markedly in the collecting ducts of obstructed kidneys, 
which is consistent with the view that local factors, such as increased 
urine flow and pressure, can be responsible for the acquired form 
of NDI by affecting the AQP2 expression
11, 12). Hypokalemia may 
cause an arginine vasopressin-resistant concentration defect
11), 
and the reduced expression of AQP2 has been demonstrated in 
hypokalemia as in the other forms of acquired NDI
13). In addition, 
a flow activated maxi-K channel and a flow-activated epithelial Na-
channel (ENaC) in the distal convoluted tubules may lower urinary 
sodium concentration by increasing sodium influx during water 
diuresis
2, 12, 14). In our patient, high urine output and hypokalemia 
may lead to the development of secondary NDI. 
Second, although our patient had a history of prematurity with 
maternal polyhydramnios, the onset of symptom started far beyond 
the neonatal period, which was consistent with classic BS. BS type 
I is usually presented with antenatal or neonatal BS
2). Antenatal 
or neonatal BS is characterized by prenatal or neonatal onset and 
life-threatening severe symptoms starting from early neonatal 
period
15). There have been several case reports of patients with BS 
type I and atypically mild symptoms of late onset
16-18). Complete 
loss of human NKCC2 transport activity was described for the 
SLC12A1 mutations associated with the severe phenotype
19). 
Pressler et al
16) suggested that the relatively mild phenotype might 
be explained by some residual activity of the affected NKCC2 
proteins. Because one of the mutations only partially impaired 
NKCC2 function, variable degrees of NKCC2 dysfunction may 
be associated with variations of the clinical phenomenon. They 
described two brothers with compound heterozygous mutations in 
the SLC12A1 gene (p.F177Y and p.D918fs), who were diagnosed 
as BS at age 13 and 15, respectively. Functional study of these two 
mutant proteins revealed that p.F177Y mutant had significant 
residual transport activity. Furthermore, they performed 36Cl-
uptake experiments after heterologous expression of wild type rat 
NKCC2 and mutated proteins in Xenopus oocytes. Functional 
analysis of the mutated rat NKCC2 protein after heterologous 
expression in Xenopus oocytes revealed significant residual 
transport activity of the NKCC2 p.F177Y mutant construct in 
contrast to no activity of the NKCC2-D918fs frameshift mutant 
construct. However, coexpression of the two mutants was not 
significantly different from that of NKCC2-F177Y alone or wild 
type. Membrane expression of NKCC2-F177Y as determined by 
luminometric surface quantification was not significantly different 
from wild-type protein, pointing to an intrinsic partial transport 
defect caused by the p.F177Y mutation. The partial function of 
NKCC2-F177Y, which was not negatively affected by NKCC2-
D918fs, therefore explained a late-onset mild phenotype-associated 
SLC12A1 gene mutation. Yamazaki et al
17) also reported a patient 
with BS type I (compound heterozygous for p.A555V and p.G809V 
mutations) who presented with asymptomatic proteinuria at age 
20 years. Our patient also has compound heterozygous missense 
mutations (p.C436Y and p.L560P). These findings suggested that 
the phenotype severity may be depend on the residual transport 
activity of the mutant NKCC2 (genotype-phenotype correlation) 
in patients with BS type I. In addition, Bettinelli et al
18) reported 
phenotypic variability in several patients with BS type I, including 
absence of hypokalemia and/or metabolic alkalosis in the first years 
of life as well as persistent metabolic acidosis mimicking distal renal 
tubular acidosis and presence of hypernatremia and hyperchloremia 
mimicking NDI.
Our patient has a karyotype of 46, XYY, a chromosomal 
anomaly. However, there has been no report of XYY syndrome 
associated with BS or NDI. XYY syndrome most often 
accompanies no medical problem and the syndrome is usually 
detected during genetic analysis for another reasons. 
In summary, BS type I may have phenotype variability including 
low urine sodium and chloride levels and later onset, and a 
definitive diagnosis can be confirmed by genetic study.
Acknowledgements
This study was supported by a grant (A080588) from the Korea 
Healthcare technology R&D Project, Ministry for Health, Welfare 
and Family Affairs, Republic of Korea.
References
  1)  Bartter FC, Pronove P, Gill JR, Maccardle RC. Hyperplasia of the 
juxtaglomerular complex with hyperaldosteronism and hypokalemic 
alkalosis. A new syndrome. Am J Med 1962;33:811-28.
 2)  Geary DF, Schaefer F. Comprehensive pediatric nephrology. 1st ed. 
Philadephia: Mosby Elsevier Co, 2008:451-9. 
 3)  Ammenti A, Montali S. ‘Neonatal variant’ of Bartter syndrome presenting 
with acidosis. Pediatr Nephrol 1996;10:79-80.
 4)  Pierratos A, Couture RA, Hierlihy PJ, Bell RC, Levine DZ. 
Bartter’s syndrome, nephrocalcinosis and renal insufficiency. CMAJ Korean J Pediatr 2010;53(8):809-813 • DOI: 10.3345/kjp.2010.53.8.809    813
1989;141:1055-7.
 5)  Proesmans W. Bartter syndrome and its neonatal variant. Eur J Pediatr 
1997;156:669-79.
 6)  Gamba G, Friedman PA. Thick ascending limb: the Na(+):K (+):2Cl(-) co-
transporter, NKCC2, and the calcium-sensing receptor, CaSR. Pflugers 
Arch 2009;458:61-76.
 7)  Vargas-Poussou R, Huang CF, Hulin P, Houillier P, Jeunemaitre X, 
Paillard M, et al. Functional characterization of a calcium-sensing receptor 
mutation in severe autosomal dominant hypocalcemia with a Bartter-like 
syndrome. J Am Soc Nephrol 2002;13:2259-66.
 8)  Hebert SC. Bartter syndrome. Curr Opin Nephrol Hypertens 
2003;12:527-32.
 9)  Birkenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz 
I, et al. Mutation of BSND causes Bartter syndrome with sensorineural 
deafness and kidney failure. Nat Genet 2001;29:310-4.
  10)  Vargas-Poussou R, Feldmann D, Vollmer M, Konrad M, Kelly L, van 
den Heuvel LPWJ, et al. Novel molecular variants of the Na-K-2Cl 
cotransporter gene are responsible for antenatal Bartter syndrome. Am J 
Hum Genet 1998 ;62:1332-40.
 11)  Geary DF, Schaefer F. Comprehensive pediatric nephrology. 1st ed. 
Philadephia: Mosby Elsevier Co, 2008:489-98.
  12)  Bockenhauer D, Cruwys M, Kleta R, Halperin LF, Wildgoose P, Souma 
T, el al. Antenatal Bartter’s syndrome: why is this not a lethal condition? 
QJM 2008;101:927-42.
  13)  Marples D, Frokiaer J, Dorup J, Knepper MA, Nielsen S. Hypokalemia-
induced downregulation of aquaporin-2 water channel expression in rat 
kidney medulla and cortex. J Clin Invest 1996; 97:1960-8.
  14)  Satlin LM, Carattino MD, Liu W, Kleyman TR. Regulation of cation 
transport in the distal nephron by mechanical forces. Am J Physiol Renal 
Physiol 2006;291:F923-31.
  15)  Jeck N, Schlingmann KP, Reinalter SC, Komhoff M, Peters M, 
Waldegger S, et al. Salt handling in the distal nephron: lessons learned 
from inherited human disorders. Am J Physiol Regul Integr Comp 
Physiol 2005;288:R782-95.
  16) Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, 
et al. Late-onset manifestation of antenatal Bartter syndrome as a result of 
residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am 
Soc Nephrol 2006;17:2136-42.
  17)  Yamazaki H, Nozu K, Narita I, Nagata M, Nozu Y, Fu XJ, et al. Atypical 
phenotype of type I Bartter syndrome accompanied by focal segmental 
glomerulosclerosis. Pediatr Nephrol 2009;24:415-8.
  18)  Bettinelli A, Ciarmatori S, Cesareo L, Tedeschi S, Ruffa G, Appiani AC, 
et al. Phenotypic variability in Bartter syndrome type I. Pediatr Nephrol 
2000;14:940-5.
  19)  Starremans PG, Kersten FF, Knoers NV, van den Heuvel LP, Bindels RJ. 
Mutations in the human Na-K-2Cl cotransporter (NKCC2) identified in 
Bartter syndrome type I consistently result in nonfunctional transporters. 
J Am Soc Nephrol 2003;14:1419-26.